Understanding and targeting the blood vessels in tumors
Official title: Identifying and exploiting molecular abnormalities of tumor vasculature
Funded at University of California, San Francisco · NIH-11128209 · Data updated 2026-11-12
This study is looking at the special features of blood vessels in tumors to find better ways to deliver cancer treatments directly to the tumors, which could help make those treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | March 13, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $607,580 |
| NIH project number | 1R01CA292649-01A1 |
| Project ID | NIH-11128209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with various types of cancer who may benefit from improved treatment strategies.
✕Less likely to help
Patients with non-cancerous conditions or those who are not eligible for cancer therapies may not receive any benefit from this research.
What this research studies
This research investigates the unique characteristics of blood vessels in tumors to improve cancer treatment. By analyzing genetic information from various cancer types, the study aims to identify specific markers that differentiate tumor blood vessels from normal ones. These markers could potentially be used to enhance the delivery of therapies directly to tumors, making treatments more effective. The research also explores whether inhibiting certain markers can lead to better outcomes in cancer models.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies by improving how treatments reach tumors.
How similar studies have gone: Previous research has shown promise in targeting tumor vasculature, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Oldham, Michael Clark — University of California, San Francisco
- Study coordinator: Oldham, Michael Clark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.